ACT Brief: Trial Simulations and Protocol Risk, RBQM Financial Value Quantified, and Three Drug Approvals

0:00-1:51

In today's ACT Brief, we examine what AI simulations surface in trial design, how RBQM delivers measurable financial returns, and three new FDA-approved treatments across hair loss, movement disorder, and bone disease.

Publisher

Applied Clinical Trials

Link

audioboom.com/posts/8958038

Published

September 29, 2026

Duration

2 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

AC

Applied Clinical Trials

@appliedclinicaltrials

#trialsimulations #rbqmfinancialvalue #drugapprovals #lifesciences

The Nile